Mirum Pharmaceuticals (MIRM) stock

Rare disease medicines , market cap $6.1B

Medicines for rare liver diseases

Worth $6.1B

Pre-market

$94.50

+0.83%

Close $93.72 +0.19%

As of 8:42 AM ET pre-market, delayed 15+ min · Live for Pro members

Quality Score

Below Average

In its industry

#109of 281

Biotech

Checks firing

2of 14

Trending down

From 52-week high

-27.9%

under its best in a year

MIRM's Quality Score fell 2 points on Fri, Nov 6, to 2. It did not trade higher than the day before.

Follow MIRM's trial news. Pro members can get an alert when Mirum Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.

Get an alert when MIRM files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ4 2026“Brelovitug AZURE-4 Phase 3 in HDV topline data expected in Q4 2026.”Trial data · SEC filing · Nov 3

Cash$561M in cash. One of the last four quarters brought cash in while the others used it.On Jun 30

Why is MIRM up?

Up 11% on Nov 4, an up day for the market: the S&P 500 rose 2%, 72% of stocks rose, and biotech stocks a median 2.1%.

Its Nov 3 results: total revenue was $185.7M, from $133.0M a year before; LIVMARLI net product sales were $133.4M, up 45%. It rose 11% on Nov 4.

Sources: Price history, Nov 4, 2026; Company release, Nov 3, 2026

1 more reason, free with an account →1 more reason why MIRM rose on Nov 4, from its filings, with the other side, the timeline, and its peers, for Pro members.

Key facts on MIRM

Key facts on MIRM
Holding it back	27.4% more shares than a year ago
Latest filing	8-K, Nov 3 Reported its quarterly results

1 more reason behind MIRM's 2, free with an account →4 more reasons behind MIRM's 2, for Pro members.

MIRM in the news

Wed Nov 4Mirum Pharmaceuticals Inc (MIRM) Q3 2026 Earnings Call Highlights: Raised Guidance, $500 ... SEC filing 4:03 PM ET · Yahoo Finance and 2 more MIRM closed +11.4% that day.

Big story

Trial

Mirum Pharmaceuticals Reports Positive Phase 3 LIVMARLI Results; Plans FDA Filing In 2027

MIRM closed +0.1% that day on 1.6x normal volume.

Reported by rttnews.com · covered by 10 outlets

Get an alert on MIRM's next big story →

Outlet counts from the GDELT Project. The move is what MIRM did that session, not a claim about why.

What's next

Wed Nov 11: Stifel Healthcare Conference 2026Investor conference · date confirmed.

2 more dates ahead: conferences, for Pro members.

Cash$561M in cash. One of the last four quarters brought cash in while the others used it.On Jun 30

MIRM catalysts

Coming up

After its last 4 reports it closed -5.3% on average, higher 1 of 4 times.

6 more coming up and 20 past catalysts since 2023, with sizes and sources, for Pro members.

What's next for MIRM, and how long its cash lasts

Next step the company has named

Q4 2026“Brelovitug AZURE-4 Phase 3 in HDV topline data expected in Q4 2026.”Trial data · SEC filing · Nov 3

What it means: the first look at a trial’s main results, as the company reports them.

Lead program: Brelovitug · Chronic Hepatitis D Infection · Phase 3
Its trial: Brelovitug vs Bulevirtide for the Treatment of Chronic Hepatitis Delta InfectionPhase 3 · Recruiting · 172 people · main data estimated Jun 30, 2027 · NCT07200908

9 more trials, 3 more milestones and 35 filings, for Pro members.

Cash runway Jun 30 balance sheet

$561M in cash

One of the last four quarters brought cash in while the others used it, so an average says little about the next.

What it means: a runway is counted only when each of the last four quarters used cash.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed Aug 12, 2025)
At-the-market share sales program (S-3ASR, filed Aug 12, 2025)

For Pro members: the amounts, and the share count against a year ago.

Insiders

CEO Christopher Peetz sold 20,000 shares on Nov 4, under a planned sale. 38 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Christopher Peetz buys or sells

For Pro members: every trade, and Christopher Peetz’s 30 filings and quotes.

Get an alert when MIRM files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 13 daysFDA decisionIn 13 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 13 daysFDA decisionIn 13 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 43 daysFDA decisionIn 43 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why MIRM scores 2

Below Averagefor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means

+2Chart checks 2 of 14 firing right now, one point each
−2Dilution 27.4% more shares outstanding than a year agoNew shares over the year: -1 at 10% more, -2 at 25% more.

Long-term trend adds
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
News adds

No effect today: Run-up, Size, Volatility, Persistence, and Insider trades.

What every line is worth, and the reason behind it, on MIRM and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:42 AM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when MIRM's Quality Score turns up

A free account. No card.

How MIRM ranks in Biotech

MIRM is #109 of 281 by Quality Score.

How MIRM ranks in Biotech
Rank	Stock	Checks	Quality Score
1	XERSXeris Biopharma	9/14	22
2	ONCBeOne Medicines	6/14	22
3	VCELVericel	8/14	21
	MEDPMedpace		Open for its score
	MGTXMeiraGTx		Open for its score
	MLTXMoonLake Immunotherapeutics		Open for its score
	MLYSMineralys Therapeutics		Open for its score
109	MIRMMirum Pharmaceuticals	2/14	2

Share count against a year before: MIRM +27%, AUPH -3.6%, BMRN +0.8%, RYTM +7.7%.

When does MIRM report earnings, and what happens after?

Expected to report Wed Feb 24, after the close (in 107 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What MIRM reported on Nov 3, 2026

The quarter

The figures are not read from the release yet.

The filing on EDGAR

Where the sales came from

MIRM's results filing gives no sales by line in a table we read.

The outlook

The outlook the company gave, by period
Measure	Figure
2026 full year
Net product sales	$715M to $720Mraised

Figures as filed (SEC filing, Nov 3)

The numbers

Market value: $6.1B; today
Sales: $618M; up 44% on the year
Free cash flow: -$229M; last 12 months

Sales grew 89% a year over 3 years, fiscal 2022 to 2025.

Its share count grew 14% a year over 3 years.

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on MIRM: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-6.5%-11.0%+11.4%

May 6Aug 5Nov 3

Reported	When	Gap	Reaction	5 days
Nov 3, 2026After close	After close	-4.5%	+11.4%	not yet
Aug 5, 2026After close	After close	-14.7%	-11.0%	-6.5%
May 6, 2026After close	After close	0.0%	-6.5%	-0.8%

MIRM closed higher after 1 of its last 4 reports.

All 4 reports, and MIRM's Quality Score going into each

MIRM sales and profit by year

Sales and profit by year

Sales grew every year from 2021 to 2025, to $521M. It lost money in each of the five years.

MIRM has 2 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on MIRM, and all 14 on every stock.Get in free →

MIRM RSI on Nov 6: 60.9, above its 50-day, below its 200-day

Not scored

RSI 60.9, MACD above signal, above its 50-day, below its 200-day. Not scored.13 readings

The deep dive on MIRM

What it does and how it makes money7 findingsAn operating loss of $22.1M in fiscal 2025, on $521M of sales.Annual report, filed Feb 25, 2026"We have rights to issued U.S. Patent No. 11,376,251, which is directed to methods of treating ALGS in a pediatric subject with maralixibat, expiring in October 2032." (10-K for fiscal 2025)SEC filing · Feb 25, 2026
Where it stands3 findingsFor Pro members3 findings on where MIRM stands: its cash, debt, and share count, for Pro members
What changed in its filings9 findings"On April 16, 2026, the Court ordered that the four pending cases against Sandoz, Hetero, Biophore and Zydus be consolidated for pretrial purposes." (10-Q for the quarter to Jun 30, 2026)SEC filing · Aug 5, 2026A new heading in its "Risk Factors" this year: "If generic manufacturers are successful in their use of litigation or regulatory means to obtain approval for generic versions of LIVMARLI, our revenue and results of operations would be adversely affected." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 25, 2026, against the one of Feb 26, 2025
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades MIRM, for Pro members
Against its closest peers4 peersShare count against a year before: MIRM +27%, AUPH -3.6%, BMRN +0.8%, RYTM +7.7%.

17 more findings on MIRM, each with its source, for Pro members.

MIRM share count over time

Shares: 27.4% more than a year ago (to Jun 30).

Shares of MIRM outstanding, as filed
Shares outstanding	As of
64.9M	Jul 31, 2026
61M	May 1, 2026
60.3M	Feb 20, 2026
51.4M	Oct 31, 2025

Offerings, shelves, and splits of MIRM, from its filings
From its filings	Filed
Registered shares for a later sale (S-3ASR)	Feb 25, 2026
Registered shares for a later sale (S-3ASR)	Aug 12, 2025

MIRM insider trades

3 insiders sold $5.4M across 3 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellEric Bjerkholt$978KChief Financial Officerat $98.37 on Sep 14, filed Sep 15

SellEric BjerkholtChief Financial Officer$978Kat $98.37 on Sep 14, filed Sep 15

All 3 insider filings on MIRM from the last six months, for Pro members.

All MIRM insider trades

MIRM's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Christopher PeetzChief Executive Officer · 9 trades
Peter RadovichPresident and COO · 4 trades
Eric BjerkholtChief Financial Officer · 7 trades
Jolanda HoweSVP, Global Controller · 9 trades
Joanne QuanChief Medical Officer · 3 trades
Saira RamasastryDirector · 7 trades
Michael G. GreyDirector · 3 trades
Patrick J. HeronDirector · 1 trade

4 more officers and directors file at MIRM.

See insider trades by person

Which ETFs hold MIRM?

In ETFs: MIRM is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

433 employeesFoster City, CAmirumpharma.com

What Mirum Pharmaceuticals says it competes with

“We face, and will continue to face, competition in the development and marketing of our products and product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies.”

From its annual report, SEC filing · Feb 25, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on MIRM and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn MIRM's score around: 8 things
7 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawaySep 15Eric Bjerkholt sold MIRM$978K at $98.37, filed Sep 15

Alerts are optional.

See MIRM's 14 chart checks

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 9, 2026: MIRM's Quality Score is 2 (Below Average), #109 of 281 in Biotech. Insiders sold $5.4M in the last 6 months (Form 4).

What does MIRM's Quality Score say?

MIRM scores 2 today, which Breakaway calls Below Average. It is #109 of 281 in Biotech by Quality Score, with 2 of 14 chart checks firing. Up 11% on Nov 4, an up day for the market: the S&P 500 rose 2%, 72% of stocks rose, and biotech stocks a median 2.1%. Shares: 27.4% more than a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is MIRM's Quality Score?

MIRM scores 2 today, which Breakaway calls Below Average (0 to 5). That is #109 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind MIRM's 2.

Are insiders buying MIRM?

3 insiders sold $5.4M across 3 filings in the last 6 months. No open-⁠market buys on record. The newest is Eric Bjerkholt, Chief Financial Officer, who sold $978K on Sep 14. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.